A preclinical consortium approach for assessing the efficacy of combined anti-CD3 plus IL-1 blockade in reversing new-onset autoimmune diabetes in NOD mice

Diabetes

Volumn 65, Issue 5, 2016, Pages 1310-1316

  Gill, Ronald G ^a   Pagni, Philippe P ^b   Kupfer, Tinalyn ^a   Wasserfall, Clive H ^c   Deng, Songyan ^d   Posgai, Amanda ^c   Manenkova, Yulia ^b   Hani, Amira Bel ^b   Straub, Laura ^e   Bernstein, Philip ^f   Atkinson, Mark A ^c   Herold, Kevan C ^d   Von Herrath, Matthias ^b   Staeva, Teodora ^g   Ehlers, Mario R ^e   Nepom, Gerald T ^h  

^a UNIVERSITY OF COLORADO   (United States)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^c UNIVERSITY OF FLORIDA   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f Immune Tolerance Network   (United States)

^g JDRF   (United States)

^h BENAROYA RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CD3 ANTIGEN; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 145 2C11; RILONACEPT; UNCLASSIFIED DRUG; HYBRID PROTEIN; IL1B PROTEIN, MOUSE; IMMUNOGLOBULIN F(AB) FRAGMENT; INSULIN; INTERLEUKIN 1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE I;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIDIABETIC ACTIVITY; ARTICLE; AUTOIMMUNE DISEASE; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETES CONTROL; DRUG EFFICACY; FEMALE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; MOUSE; NONHUMAN; PANCREAS ISLET BETA CELL; PILOT STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; TREATMENT DURATION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; CHEMISTRY; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION; DRUG EFFECTS; GERMFREE ANIMAL; IMMUNOLOGY; IMMUNOTHERAPY; MEDICAL RESEARCH; METABOLISM; METHODOLOGY; MULTICENTER STUDY (TOPIC); NONOBESE DIABETIC MOUSE; PROCEDURES; REPRODUCIBILITY; SECRETION (PROCESS); UNITED STATES;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD3; AUTOIMMUNE DISEASES; BIOMEDICAL RESEARCH; DIABETES MELLITUS, TYPE 1; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOTHERAPY; INSULIN; INSULIN-SECRETING CELLS; INTERLEUKIN-1 RECEPTOR ACCESSORY PROTEIN; INTERLEUKIN-1BETA; MICE, INBRED NOD; MULTICENTER STUDIES AS TOPIC; PILOT PROJECTS; RECEPTORS, INTERLEUKIN-1 TYPE I; RECOMBINANT FUSION PROTEINS; REPRODUCIBILITY OF RESULTS; RESEARCH DESIGN; SPECIFIC PATHOGEN-FREE ORGANISMS; UNITED STATES;

EID: 84964681152     PISSN: 00121797     EISSN: 1939327X     Source Type: Journal    
DOI: 10.2337/db15-0492     Document Type: Article

References (23)

1. Matthews JB, Staeva TP, Bernstein PL, Peakman M, von Herrath M; ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Developing combination immunotherapies for type 1 diabetes: recommendations from the ITN-JDRF Type 1 Diabetes Combination Therapy Assessment Group. Clin Exp Immunol 2010;160:176-184
2. Jucker M. The benefits and limitations of animal models for translational research in neurodegenerative diseases. Nat Med 2010;16:1210-1214
3. Atkinson MA. Evaluating preclinical efficacy. Sci Transl Med 2011;3:96cm22
4. Landis SC, Amara SG, Asadullah K, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature 2012;490:187-191
5. Peers IS, South MC, Ceuppens PR, Bright JD, Pilling E. Can you trust your animal study data? Nat Rev Drug Discov 2014;13:560
6. Steward O, Popovich PG, Dietrich WD, Kleitman N. Replication and reproducibility in spinal cord injury research. Exp Neurol 2012;233:597-605
7. Herold KC, Bluestone JA, Montag AG, et al. Prevention of autoimmune diabetes with nonactivating anti-CD3 monoclonal antibody. Diabetes 1992;41:385-391
8. Chatenoud L, Thervet E, Primo J, Bach JF. Anti-CD3 antibody induces longterm remission of overt autoimmunity in nonobese diabetic mice. Proc Natl Acad Sci U S A 1994;91:123-127
9. Hu CY, Rodriguez-Pinto D, Du W, et al. Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in mice. J Clin Invest 2007;117:3857-3867
10. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-1698
11. Herold KC, Gitelman SE, Ehlers MR, et al; AbATE Study Team. Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with newonset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders. Diabetes 2013;62:3766-3774
12. Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al.; Type 1 Diabetes TrialNet Anti-CD20 Study Group. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-2152
13. Rabinovitch A, Suarez-Pinzon WL, Shapiro AM, Rajotte RV, Power R. Combination therapy with sirolimus and interleukin-2 prevents spontaneous and recurrent autoimmune diabetes in NOD mice. Diabetes 2002;51:638-645
14. Long SA, Rieck M, Sanda S, et al. Diabetes TrialNet and the Immune Tolerance Network. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function. Diabetes 2012;61:2340-2348
15. Ablamunits V, Henegariu O, Hansen JB, et al. Synergistic reversal of type 1 diabetes in NOD mice with anti-CD3 and interleukin-1 blockade: evidence of improved immune regulation. Diabetes 2012;61:145-154
16. Atkinson MA, Maclaren NK, Luchetta R. Insulitis and diabetes in NOD mice reduced by prophylactic insulin therapy. Diabetes 1990;39:933-937
17. Economides AN, Carpenter LR, Rudge JS, et al. Cytokine traps: multicomponent, high-affinity blockers of cytokine action. Nat Med 2003;9:47-52
18. Grant CW, Moran-Paul CM, Duclos SK, Guberski DL, Arreaza-Rubín G, Spain LM. Testing agents for prevention or reversal of type 1 diabetes in rodents. PLoS One 2013;8:e7w989
19. Valle A, Jofra T, Stabilini A, Atkinson M, Roncarolo MG, Battaglia M. Rapamycin prevents and breaks the anti-CD3-induced tolerance in NOD mice. Diabetes 2009;58:875-881
20. Perl S, Perlman J, Weitzel RP, Phang O, Hsieh MM, Tisdale J. Addition of rapamycin to anti-CD3 antibody improves long-term glycaemia control in diabetic NOD mice. PLoS One 2013;8:e67189
21. Wen L, Ley RE, Volchkov PY, et al. Innate immunity and intestinal microbiota in the development of type 1 diabetes. Nature 2008;455:1109-1113
22. Atkinson MA, Chervonsky A. Does the gut microbiota have a role in type 1 diabetes? Early evidence from humans and animal models of the disease. Diabetologia 2012;55:2868-2877
23. Baker D, Amor S. Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely. Mult Scler Relat Disord 2014;3:555-564